Epsilogen licences experimental IgE antibody from KCL
The antibody, developed at KCL in collaboration with Cancer Research UK, is the first therapeutic IgE antibody to enter clinical trials
Read More
Tag: MOv18
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
